Disclosed are formulations and dosage forms of avermectins, and particularly of ivermectin. The disclosed compositions may be used in methods for the treatment and prevention of various neurological disorders in humans.

The present invention relates to a method, in particular an in vitro method, for diagnosing an inflammatory disease in a human patient, comprising detecting IL-1 producing Th17 cells in a sample comprising T cells obtained from said patient comprising detecting gasdermin E protein expression, wherein the presence of said IL-1 producing Th17 cells is indicative for an inflammatory disease in the human patient. The inflammatory disease is selected from the group of an inflammation that is caused or exacerbated by IL-1 producing Th17 cells, inflammation caused or related to danger signal IL-1. The present invention further relates to methods for diagnosing the status of an inflammatory disease in a human patient, or for identifying an inflammation modulating compound, such as an anti-inflammatory compound. Furthermore, the present invention relates to a kit for performing the above methods. Finally, improved inflammation modulating, and in particular anti-inflammatory compounds or pharmaceutical compositions are provided.

The invention provides methods and systems for detecting a biomarker in a synovial fluid wherein the system also includes a control to ensure that the test sample is indeed synovial fluid. The biomarkers and the control for synovial fluid can be identified using proteomic methods, including but not limited to antibody based methods, such as an enzyme-linked immunosorbant assay (ELISA), a radioimmunoassay (RIA), or a lateral flow immunoassay.

Biomarker panels for the prediction of patient response to immunotherapy, and methods of use thereof.

The disclosure relates to methods for redirecting an active form of an endogenous cytokine to a target cell or target tissue of interest in a biological system or subject in need thereof by administering a multi-specific binding molecule comprising (a) a binding domain that specifically binds to an active form of a cytokine and (b) a binding domain that specifically binds to an epitope on a molecule that is a marker on a target cell or tissue, wherein the multi-specific binding molecule, when bound to the cytokine, does not block or only partially blocks, the ability of the cytokine to bind to and agonize a cognate receptor for the cytokine.

The disclosure relates to methods for redirecting an active form of an endogenous cytokine to a target cell or target tissue of interest in a biological system or subject in need thereof by administering a multi-specific binding molecule comprising (a) a binding domain that specifically binds to an active form of a cytokine and (b) a binding domain that specifically binds to an epitope on a molecule that is a marker on a target cell or tissue, wherein the multi-specific binding molecule, when bound to the cytokine, does not block or only partially blocks, the ability of the cytokine to bind to and agonize a cognate receptor for the cytokine.

The invention provides methods and systems for detecting a biomarker in a synovial fluid wherein the system also includes a control to ensure that the test sample is indeed synovial fluid. The biomarkers and the control for synovial fluid can be identified using proteomic methods, including but not limited to antibody based methods, such as an enzyme-linked immunosorbant assay (ELISA), a radioimmunoassay (RIA), or a lateral flow immunoassay.

Provided herein is a method for measuring the levels of chronic inflammaging (SCI) of a subject. In some embodiments, the method may comprise measuring the amount of two or more of the proteins C-X-C motif ligand 9 (CXCL9), TNF-related apoptosis-inducing ligand (TRAIL), interferon gamma (IFNG), eosinophil chemotactic protein (EOTAXIN) and growth-regulated alpha protein (GROA) in a sample (e.g., blood serum) from the subject calculating a score based on the weighted amounts of each of those proteins.

Compositions and methods are disclosed herein for the treatment of neurocognitive disorders or central nervous system (CNS) disorders such as Alzheimer's disease (AD) and congenital heart diseases such as hypoplastic left heart syndrome (HLHS) with allogeneic mesenchymal stem cells (MSCs). The methods of treatment involve an administration of a composition of allogeneic mesenchymal stem cells to a subject in need thereof, wherein the effectiveness of the treatment methods can be determined through the measurement of specific biomarkers.

The present invention relates to the human Interleukin 1 Receptor antagonist anakinra for use in the treatment of Post-Acute COVID Syndrome (PACS), wherein said treatment comprises administration of a dose of at least approximately 100 mg of anakinra to a patient in need thereof. Also, related treatment methods and pharmaceutical compositions for said use are disclosed.